Titlebook: Gastrointestinal Stromal Tumors; Bench to Bedside Charles R. Scoggins,Chandrajit P. Raut,John T. Mul Book 2017 Springer International Publi

glamor

History of GIST,treated on a clinical trial with imatinib, a tyrosine kinase receptor inhibitor of KIT. Today, imatinib is approved for use in advanced/metastatic GIST and as adjuvant therapy. Future advances require an understanding of the molecular biology of when imatinib is ineffective, which will open opportunities for new treatments.

Yourself

Operative Management of Gastrointestinal Stromal Tumorshas led to more tailored resections and an expanded role of minimally invasive approaches. This chapter will focus on the open surgical approaches; apply these concepts in the operative management of primary GIST.

改良

玷污

高興去去

probate

NEG

Advances on Molecular Characterization and Targeted Therapies on GISTeen improved based on recent molecular discoveries. The irruption of tyrosine kinase inhibitors in the field revolutionized the treatment of patients with GIST and became a paradigm of translational research in modern oncology. In this chapter, we would like to discuss the most recent advances in targeted therapy for patients with GIST.

截斷

Management of Liver Metastases of Gastrointestinal Stromal Tumorsopriate patient selection based on presentation and TKI response guides therapy. Salvage therapy may be possible for patients with GIST patients with hepatic metastases. This chapter reviews the clinical decision-making necessary for effective management of GIST hepatic metastases.

半圓鑿

https://doi.org/10.1007/978-3-642-38186-7n by mutations leading to increased kinase signaling. In contrast, GIST occurring as a part of Carney Triad, Carney-Stratakis Dyad, and hereditary paraganglioma syndromes has unique underlying biology, epidemiology, clinic-pathologic features, and disease course (Table 1).

浮雕

Inherited GIST,n by mutations leading to increased kinase signaling. In contrast, GIST occurring as a part of Carney Triad, Carney-Stratakis Dyad, and hereditary paraganglioma syndromes has unique underlying biology, epidemiology, clinic-pathologic features, and disease course (Table 1).